Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Back In Biotech, Waksal's Kadmon Emerges From Stealth Mode To Focus on Hep C

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal with Valeant brings development and commercialization rights to ribavirin analog that could have better safety profile for anemia.

You may also be interested in...



Kadmon Reveals A Bit Of Its Hand To Investors

Kadmon CEO Sam Waksal - the former CEO of ImClone - laid out the startup's ambitious pipeline during the Jeffries Healthcare Conference.

Kadmon Reveals A Bit Of Its Hand To Investors

Kadmon CEO Sam Waksal - the former CEO of ImClone - laid out the startup's ambitious pipeline during the Jeffries Healthcare Conference.

Infergen Promotion Produced By Third Party Lands Kadmon In Hot Water With DDMAC

FDA's Division of Drug Marketing, Advertising and Communications cites Kadmon for failing to include risk information and overstating efficacy in a "STATgram" promoting its hepatitis C treatment interferon alfacon-1.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel